Prognostic value of MRD monitoring based on BCR-ABL1 copy numbers in Philadelphia chromosome positive acute lymphoblastic leukemia. Issue 14 (5th December 2020)

• Record Type: Journal Article
• Authors: Arunachalam, Arun Kumar; Janet, Nancy Beryl; Korula, Anu; Lakshmi, Kavitha M.; Kulkarni, Uday P.; Aboobacker, Fouzia N.; Abraham, Aby; George, Biju; Balasubramanian, Poonkuzhali; Mathews, Vikram
• Is Part Of: Leukemia & lymphoma. Volume 61:Issue 14(2020)
• Page Start: 3468
• Page End: 3475
• Publication Date: 2020-12-05
• Subjects: Ph + ALL -- BCR-ABL1 -- minimal residual disease -- RQ-PCR; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2020.1811272
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Assessment of measurable residual disease (MRD) has emerged as a powerful prognostic tool in pediatric and adult acute lymphoblastic leukemia (ALL). In this single-centre retrospective study, we evaluated the prognostic relevance of MRD based on BCR-ABL1 copy numbers in Ph + ALL patients between 2006 and 2018. Molecular responses were evaluated at 3, 6, 9 and 12 months after the initiation of treatment. Patients who had their MRD assessed at three or more time points were categorized into MRD good risk or poor risk based on BCR-ABL1/ABL1 copy number ratio. MRD positive patients consistently showed a trend toward poor survival and on multivariate analysis, MRD poor risk patients had adverse outcomes when compared to MRD good risk patients in terms of overall (OS; p = .031) and event-free (EFS; p < .001) survival. In conclusion, molecular MRD based on BCR-ABL1 copy number ratio is an ideal prognostic indicator in Ph + ALL patients undergoing treatment.